These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33669310)

  • 21. Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.
    de Castro SL; Batista DG; Batista MM; Batista W; Daliry A; de Souza EM; Menna-Barreto RF; Oliveira GM; Salomão K; Silva CF; Silva PB; Soeiro Mde N
    Mol Biol Int; 2011; 2011():306928. PubMed ID: 22091400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
    Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
    Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
    Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germacranolide-type sesquiterpene lactones from Smallanthus sonchifolius with promising activity against Leishmania mexicana and Trypanosoma cruzi.
    Ulloa JL; Spina R; Casasco A; Petray PB; Martino V; Sosa MA; Frank FM; Muschietti LV
    Parasit Vectors; 2017 Nov; 10(1):567. PubMed ID: 29132413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of
    Reigada C; Sayé M; Phanstiel O; Valera-Vera E; Miranda MR; Pereira CA
    Front Med (Lausanne); 2019; 6():256. PubMed ID: 31781568
    [No Abstract]   [Full Text] [Related]  

  • 28. Biological activity of the azlactone derivative EPA-35 against Trypanosoma cruzi.
    de Azeredo CM; Ávila EP; Pinheiro DL; Amarante GW; Soares MJ
    FEMS Microbiol Lett; 2017 Feb; 364(4):. PubMed ID: 28130370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
    Ogindo CO; Khraiwesh MH; George M; Brandy Y; Brandy N; Gugssa A; Ashraf M; Abbas M; Southerland WM; Lee CM; Bakare O; Fang Y
    Bioorg Med Chem; 2016 Aug; 24(16):3849-55. PubMed ID: 27345756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.
    Botero A; Keatley S; Peacock C; Thompson RC
    Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):34-41. PubMed ID: 28040568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
    Duschak VG
    Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
    Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, molecular modelling, and in vitro evaluation of tricyclic coumarins against Trypanosoma cruzi.
    Coelho GS; Andrade JS; Xavier VF; Sales Junior PA; Rodrigues de Araujo BC; Fonseca KDS; Caetano MS; Murta SMF; Vieira PM; Carneiro CM; Taylor JG
    Chem Biol Drug Des; 2019 Mar; 93(3):337-350. PubMed ID: 30362274
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Souza JM; Vieira TM; Candido ACBB; Tezuka DY; Rao GS; de Albuquerque S; Crotti AEM; Siqueira-Neto JL; Magalhães LG
    Curr Res Parasitol Vector Borne Dis; 2021; 1():100031. PubMed ID: 35284878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammea type coumarins isolated from Calophyllum brasiliense induced apoptotic cell death of Trypanosoma cruzi through mitochondrial dysfunction, ROS production and cell cycle alterations.
    Rodríguez-Hernández KD; Martínez I; Reyes-Chilpa R; Espinoza B
    Bioorg Chem; 2020 Jul; 100():103894. PubMed ID: 32388434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of "reversed" diamidines against Trypanosoma cruzi "in vitro".
    Silva CF; Batista MM; Mota RA; de Souza EM; Stephens CE; Som P; Boykin DW; Soeiro Mde N
    Biochem Pharmacol; 2007 Jun; 73(12):1939-46. PubMed ID: 17462605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi.
    Simões-Silva MR; De Araújo JS; Peres RB; Da Silva PB; Batista MM; De Azevedo LD; Bastos MM; Bahia MT; Boechat N; Soeiro MNC
    Parasitology; 2019 Jul; 146(8):1006-1012. PubMed ID: 30859917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes.
    Sykes ML; Avery VM
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):215-28. PubMed ID: 27120069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trypanosoma cruzi: in vitro activity of Epoxy-alpha-Lap, a derivative of alpha-lapachone, on trypomastigote and amastigote forms.
    Bourguignon SC; Castro HC; Santos DO; Alves CR; Ferreira VF; Gama IL; Silva FC; Seguins WS; Pinho RT
    Exp Parasitol; 2009 Jun; 122(2):91-6. PubMed ID: 19285074
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.